SOLV · 10-Q · 2026Q3 · Full report

Products and Technology

Solventum Corp · 2026-11-05 · Importance 13 · Surprise 6

MedSurg growth was led by I.V. site management and negative pressure wound therapy products, including Tegaderm CHG within Infection Prevention and Surgical Solutions. The company said its SKU rationalization program partially offset growth, with a larger impact on Infection Prevention and Surgical Solutions. Dental Solutions growth over the first nine months was driven by restorative and prevention solutions and orthodontics, with both volume and price contributing and new products launched in the prior year leading growth. Health Information Systems growth was attributed to continued adoption of Solventum 360 Encompass.

Key facts

• Solventum acquired privately held bioscience company Acera Surgical in December 2025. source
• Health Information Systems' third-quarter 2026 organic growth was driven by continued adoption of Solventum 360 Encompass. source
• Continued adoption of Solventum 360 Encompass and performance management solutions drove positive organic growth in Health Information Systems. source
• Solventum had no acquisitions during the three and nine months ended September 30, 2026 or 2025. source